Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: Towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1936-1945

  Becquet, Renaud ^a,b   Ekouevi, Didier K ^a,b,f   Arrive, Elise ^a,b   Stringer, Jeffrey S A ^g,h   Meda, Nicolas ⁱ   Chaix, Marie Laure ^c,d   Treluyer, Jean Marc ^c,e   Leroy, Valériane ^a,b   Rouzioux, Christine ^c,d   Blanche, Stéphane ^c,d   Dabis, François ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Centre Hospitalier Universitaire Cochin Saint Vincent de Paul ^*  (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^g CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; BREAST FEEDING; BREAST MILK; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT FEEDING; NONHUMAN; NUTRITIONAL COUNSELING; PERINATAL PERIOD; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SAFETY; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 72049128292     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648446     Document Type: Review

References (74)

1. UNAIDS. AIDS epidemic update. Geneva, Switzerland: United Nations program on HIV/AIDS, 2008.
2. Becquet R, Newell ML. Prevention of postnatal HIV infection: infant feeding and antiretroviral interventions. Curr Opin HIV AIDS 2007; 2:361-366 (Pubitemid 47254730)
3. Médecins sans frontières. Responding to the failure of prevention of mother-to-child transmission (PMTCT) programmes: what needs to change? Expert roundtable 23. 24 June 2008. Available at: http://www.msfaccess. org/main/hiv-aids/pmtct-experts-roundtable/. Accessed 16 July 2009.
4. Orne-Gliemann J, Becquet R, Ekouevi DK, Leroy V, Perez F, Dabis F. Children and HIV/AIDS: from research to policy and action in resource-limited settings. AIDS 2008; 22:797-805. (Pubitemid 351563828)
5. UNICEF. Children and AIDS: second stocktaking report. 2008. Available at: http://www. unicef.org/publications/files/ChildrenAIDS-SecondStocktakingReport. pdf. Accessed 16 July 2009.
6. Leroy V, Karon JM, Alioum A, et al. Twentyfour month efficacy of a maternal short-course zidovudine regimen to prevent mother-tochild transmission of HIV-1 in West Africa. AIDS 2002; 16:631-641 (Pubitemid 34218860)
7. Becquet R, Ekouevi DK, Menan H, et al. Early mixed feeding and breastfeeding beyond six months increase the risk of postnatal HIV transmission: ANRS 1201/1202 Ditrame Plus, Abidjan, Côte d'Ivoire. Prev Med 2008; 47: 27-33.
8. Leroy V, Ekouevi DK, Becquet R, et al. 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-tochild transmission. PLoS ONE 2008; 3:el645.
9. Rollins NC, Becquet R, Bland RM, Coutsoudis A, Coovadia HM, Newell ML. Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritisation within programs. AIDS 2008; 22:2349-2357
10. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning for HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141 (Pubitemid 351962036)
11. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered Approach. PLoS Medicine 2007; 4:e257.
12. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005; 19:1865-1875
13. Breastfeeding and HIV International Transmission Study Group (BHITS). Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-2166
14. Becquet R, Bequet L, Ekouevi DK, et al. Twoyear morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire. PLoS Medicine 2007; 4:el7.
15. Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. JAMA 2001; 286: 2413-2420 (Pubitemid 33098159)
16. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805. (Pubitemid 44223103)
17. Bahl R, Frost C, Kirkwood BR, et al. Infant feeding patterns and risks of death and hospitalization in the first half of infancy multicentre cohort study. Bull World Health Organ 2005; 83:418-426 (Pubitemid 40868438)
18. Doherty T, Chopra M, Nkonki L, Jackson D, Greiner T. Effect of the HIV epidemic on infant feeding in South Africa: "when they see me coming with the tins they laugh at me.". Bull World Health Organ 2006; 84:90-96
19. Mach O, Lu L, Creek T, et al. Populationbased study of a widespread outbreak of diarrhea associated with increased mortality and malnutrition in Botswana, January-March, 2006. Am J Trop Med Hyg 2009; 80:812-818
20. Becquet R. Antiretroviral therapy among HIVinfected breastfeeding mothers: a promising strategy to prevent HIV transmission through breastmilk in Africa. Future HIV Therapy 2007; 1:17-21.
21. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
22. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-929
23. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a doubleblind placebo-controlled multicentre trial. DI- TRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet 1999; 353: 786-792
24. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and singledose nevirapine to prevent peripartum transmission of HIV. The ANRS 1201/1202 Ditrame Plus study, Abidjan, Cote d'Ivoire. AIDS 2005; 19:309-318 (Pubitemid 40396563)
25. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
26. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228 (Pubitemid 38916040)
27. Petra study team. Efficacy of three shortcourse regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study) : a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-1186
28. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773-780
29. Wiktor SZ, Ekpini E, Karon JM, et al. Shortcourse oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-785
30. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a metaanalysis. International Journal of Epidemiology 2007; 36:1009-1021 (Pubitemid 350018545)
31. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-487 (Pubitemid 43202738)
32. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6: e1000172.
33. Chi BH, Sinkala M, Mbewe F, et al. Singledose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705 (Pubitemid 350100773)
34. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240 (Pubitemid 38922817)
35. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147 (Pubitemid 46089674)
36. Come PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-tochild transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 2008; 46:611-621
37. WHO, UNICEF, UNAIDS. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland. 2008.
38. Cohen MH, Olszewski Y, Webber MP, et al. Women identified with HIV at labor and delivery: testing, disclosing and linking to care challenges. Matern Child Health J 2008; 12: 568-576
39. Mkwanazi NB, Patel D, Newell M-L, et al. Rapid testing may not improve uptake of HIV testing and same day results in a rural South African community: a cohort study of 12,000 women. PLoS ONE 2008; 3:e3501.
40. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002; 359: 2097-2104 (Pubitemid 34680979)
41. Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. PLoS One 2009; 4:e7397.
42. Leroy V, Karon JM, Alioum A, et al. Postnatal transmission of HIV-1 after a maternal shortcourse zidovudine peripartum regimen in West Africa. AIDS 2003; 17:1493-1501 (Pubitemid 36900550)
43. Giuliano M, Guidotti G, Andreotti M, et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the drug resource enhancement against AIDS and malnutrition program. J Acquir Immune Defic Syndr 2007; 44:286-291 (Pubitemid 46328344)
44. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005; 192:713-719
45. Ekouevi DK, Inwoley A, Tonwe-Gold B, et al. Variation of CD4 count and percentage among women receiving antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIV: Implication for HAART initiation in resource-limited settings. AIDS Research and Human Retroviruses 2007; 23:1469-1474
46. De Vincenzi I, Kesho Bora Study Group. HIVfree survival at 12 months among children born to HIV-infected women receiving antiretrovirals from 34 to 36 weeks of pregnancy [abstract 638]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
47. De Vincenzi I, Kesho Bora Study Group. Triple-antiretroviral (ARV) prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-tochild transmission of HIV-1 (MTCT): The Kesho Bora Randomized Controlled Clinical Trial in Five Sites in Burkina Faso, Kenya and South Africa (trial registration number ISRCTN71468401) [abstract LBPECO1]. In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis and Treatment (Cape Town, South Africa). 2009.
48. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826
49. Phillips A. Morbidity and mortality in the HAART era [abstract 8]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
50. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353: 1463-1468
51. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
52. El-Sadr W, SMART study group. Re-initiation of ART in the CD4-guided ART interruption group in the SMART study lowers risk of opportunistic disease or death [abstract 38]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
53. Danel C, Moh R, Chaix ML, et al. Twomonths-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis 2009; 199:66-76.
54. WHO. Consensus statement of the WHO HIV and infant feeding technical consultation held on behalf of the Inter-agency Task Team (IATT) on prevention of HIV infections in pregnant women, mothers and their Infants, Geneva, October 25-27, 2006. Available at: http://www.who.int/child-adolescent-health/New- Publications/NUTRITION/consensus -statement.pdf. Accessed 16 July 2009.
55. Becquet R, Leroy V, Ekouevi DK, et al. Complementary feeding adequacy in relation to nutritional status among early weaned breastfed children who are born to HIV-infected mothers: ANRS 1201/1202 Ditrame Plus, Abidjan, Côte d'Ivoire. Pediatrics 2006; 117: e701-10. (Pubitemid 46071474)
56. Cames C, Mouquet C, Ayassou K, et al. A sustainable baby food support for HIV-1-infected mothers. The Kesho Bora study initiative in Bobo Dioulasso, Burkina Faso [poster TUPE0356]. In: Program and abstracts of the PXVI International AIDS conference (Toronto, Canada). 2006.
57. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362:1171-1177 (Pubitemid 37255341)
58. Kilewo C, Karlsson K, Massawe A, et al. Pre- vention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: The Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315-323
59. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129
60. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009; 4:e4096.
61. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313
62. Vyankandondera J, Luchters S, Hassink E. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBAstudy) [oral communication LB7]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris, France). 2003.
63. Shearer WT. Breastfeeding and HIV infection. Pediatrics 2008; 121:1046-1047
64. Chasela C, Hudgens M, Jamieson D, et al. Both maternal HAART and daily infant nevirapine (NVP) are effective in reducing HIV1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breastfeeding, Antiretroviral and Nutrition (BAN) Study [abstract WELBC103]. In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis and Treatment (Cape Town, South Africa). 2009.
65. Lehman DA, Chung MH, John-Stewart GC, et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-tochild transmission. Aids 2008; 22:1475-1485
66. Thomas T, Masaba R, Ndivo R, et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu breastfeeding study, Kisumu, Kenya, 2003-2007 [abstract 45aLB]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
67. Peltier A, Ndayisaba G, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009 [Epub ahead of print].
68. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers prophylactically with triple antiretroviral therapy in Dar es Salaam, Tanzania: the MITRA PLUS study. In: Program and abstracts of the 3rd Conference on HIV Pathogenesis and Treatment (Rio De Janeiro, Brazil). 2005.
69. Marazzi MC, Palombi L, Liotta G, et al. Decrease in HIV-1 mother-to-child transmission in women receiving postnatal HAART: 12month follow-up data [abstract 668]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.
70. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program a experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21(Suppl 4):S65-71. (Pubitemid 47051751)
71. Shapiro R, Hughes M, Ogwu A, et al. A ran- domized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child HIV transmission among breastfeeding women in Botswana (The Mma Bana Study) [abstract WELBB101]. In: Program and abstracts of the 5th IAS Conference on HIV Pathogenesis and Treatment (Cape Town, South Africa). 2009.
72. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving HAART. Antimicrob Agents Chemother 2009; 53:1170-1176
73. Bae WH, Wester C, Smeaton LM, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 2008; 22:1633-1640
74. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf 2007; 30:203-213